List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7205553/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nature Immunology, 2022, 23, 275-286.	7.0	95
2	Neurogenesis and Viral Infection. Frontiers in Immunology, 2022, 13, 826091.	2.2	8
3	Host Restriction Factors Modulating HIV Latency and Replication in Macrophages. International Journal of Molecular Sciences, 2022, 23, 3021.	1.8	9
4	Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding. Thrombosis and Haemostasis, 2022, 122, 984-997.	1.8	12
5	Reply to: Hultström et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19. Nature Immunology, 2022, 23, 865-867.	7.0	4
6	TRIM22. A Multitasking Antiviral Factor. Cells, 2021, 10, 1864.	1.8	21
7	<scp>The importance of naturally attenuated SARS oV</scp> â€2 <scp>in the fight against COVID</scp> â€19. Environmental Microbiology, 2020, 22, 1997-2000.	1.8	54
8	Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin. Thrombosis and Haemostasis, 2020, 120, 1700-1715.	1.8	228
9	Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines. Virus Research, 2019, 269, 197631.	1.1	10
10	The ATP/P2X7 axis in human immunodeficiency virus infection of macrophages. Current Opinion in Pharmacology, 2019, 47, 46-52.	1.7	9
11	Subverting the mechanisms of cell death: flavivirus manipulation of host cell responses to infection. Biochemical Society Transactions, 2018, 46, 609-617.	1.6	26
12	The interferon-stimulated gene TRIM22 : A double-edged sword in HIV-1 infection. Cytokine and Growth Factor Reviews, 2018, 40, 40-47.	3.2	26
13	Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization. Scientific Reports, 2018, 8, 14249.	1.6	23
14	Study of 2009 H1N1 Pandemic Influenza Virus as a Possible Causative Agent of Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4343-4356.	1.8	16
15	Zika Virus Replication in Dorsal Root Ganglia Explants from Interferon Receptor1 Knockout Mice Causes Myelin Degeneration. Scientific Reports, 2018, 8, 10166.	1.6	20
16	Mutations Conferring Increased Sensitivity to Tripartite Motif 22 Restriction Accumulated Progressively in the Nucleoprotein of Seasonal Influenza A (H1N1) Viruses between 1918 and 2009. MSphere, 2018, 3, .	1.3	14
17	5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract. Antiviral Research, 2017, 142, 16-20.	1.9	6
18	Human Endometrial Stromal Cells Are Highly Permissive To Productive Infection by Zika Virus. Scientific Reports, 2017, 7, 44286.	1.6	50

#	Article	IF	CITATIONS
19	Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control. Scientific Reports, 2017, 7, 42470.	1.6	21
20	Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Research, 2017, 140, 13-17.	1.9	88
21	Chronically infected T-cell lines become handy for a novel assay measuring the reservoir of replication-competent HIV-1. Aids, 2017, 31, 2555-2556.	1.0	1
22	HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nature Communications, 2017, 8, 498.	5.8	78
23	Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. Frontiers in Immunology, 2017, 8, 564.	2.2	16
24	Plastic restriction of HIV-1 replication in human macrophages derived from M1/M2 polarized monocytes. Journal of Leukocyte Biology, 2016, 100, 1147-1153.	1.5	15
25	Immuno-Pharmacological Targeting of Virus-Containing Compartments in HIV-1-Infected Macrophages. Trends in Microbiology, 2016, 24, 558-567.	3.5	15
26	Zika Virus: a re-emerging pathogen with rapidly evolving public health implications. New Microbiologica, 2016, 39, 86-90.	0.1	6
27	HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter. Retrovirology, 2015, 12, 104.	0.9	62
28	Inhibition of influenza H5N1 invasion by modified heparin derivatives. MedChemComm, 2015, 6, 640-646.	3.5	40
29	HIV-1 Isolation from Infected Peripheral Blood Mononuclear Cells. Methods in Molecular Biology, 2014, 1087, 187-196.	0.4	3
30	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. Journal of Translational Medicine, 2014, 12, 335.	1.8	13
31	Lentiviral Effector Pathways of TRIM Proteins. DNA and Cell Biology, 2014, 33, 191-197.	0.9	15
32	Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature, 2014, 516, 418-422.	13.7	300
33	Differential impacts of R5 vs. X4 HIV-1 on the transcriptome of primary CD4+ T cells. Retrovirology, 2013, 10, .	0.9	1
34	Influenza A Viruses Grow in Human Pancreatic Cells and Cause Pancreatitis and Diabetes in an Animal Model. Journal of Virology, 2013, 87, 597-610.	1.5	54
35	TRIM22 Inhibits Influenza A Virus Infection by Targeting the Viral Nucleoprotein for Degradation. Journal of Virology, 2013, 87, 4523-4533.	1.5	195
36	Novel genetic association of TNF-α-238 and PDCD1-7209 polymorphisms with long-term non-progressive HIV-1 infection. International Journal of Infectious Diseases, 2013, 17, e845-e850.	1.5	14

#	Article	IF	CITATIONS
37	Novel factors interfering with human immunodeficiency virusâ€ŧype 1 replication <i>in vivo</i> and <i>in vitro</i> . Tissue Antigens, 2013, 81, 61-71.	1.0	18
38	Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. Aids, 2013, 27, 2335-2344.	1.0	17
39	Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. Molecular Therapy, 2013, 21, 175-184.	3.7	72
40	M1 polarization of human monocyte-derived macrophages restricts pre and postintegration steps of HIV-1 replication. Aids, 2013, 27, 1847-1856.	1.0	54
41	The Puzzling Role of CXCR4 in Human Immunodeficiency Virus Infection. Theranostics, 2013, 3, 18-25.	4.6	23
42	Single-Nucleotide Polymorphism–Defined Class I and Class III Major Histocompatibility Complex Genetic Subregions Contribute to Natural Long-term Nonprogression in HIV Infection. Journal of Infectious Diseases, 2012, 205, 718-724.	1.9	28
43	HIV-1 envelope-dependent restriction of CXCR4-using viruses in child but not adult untransformed CD4+ T-lymphocyte lines. Blood, 2012, 119, 2013-2023.	0.6	6
44	A General Strategy to Endow Natural Fusion-protein-Derived Peptides with Potent Antiviral Activity. PLoS ONE, 2012, 7, e36833.	1.1	67
45	Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers. Medicina Del Lavoro, 2012, 103, 220-9.	0.3	2
46	Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. Aids, 2011, 25, 177-183.	1.0	40
47	Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors. Future Virology, 2011, 6, 521-533.	0.9	1
48	TRIM22 Inhibits HIV-1 Transcription Independently of Its E3 Ubiquitin Ligase Activity, Tat, and NF-κB-Responsive Long Terminal Repeat Elements. Journal of Virology, 2011, 85, 5183-5196.	1.5	87
49	A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes. PLoS ONE, 2011, 6, e28001.	1.1	49
50	Restriction factors of retroviral replication: the example of Tripartite Motif (TRIM) protein 5 $\hat{l}\pm$ and 22. Amino Acids, 2010, 39, 1-9.	1.2	16
51	Asymmetric HIV-1 co-receptor use and replication in CD4+ T lymphocytes. Journal of Translational Medicine, 2010, 9, S8.	1.8	13
52	Nef-specific CD45RA+ CD8+ T cells secreting MIP-1β but not IFN-γ are associated with nonprogressive HIV-1 infection. AIDS Research and Therapy, 2010, 7, 20.	0.7	8
53	Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukinâ€2. HIV Medicine, 2010, 11, 349-352.	1.0	1
54	Pandemic Vaccine Preparedness—Have We Left Something Behind?. PLoS Pathogens, 2009, 5, e1000482.	2.1	16

#	Article	IF	CITATIONS
55	Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. , 2009, 123, 310-322.		82
56	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2
57	Post-entry events of efficient R5 vs. inefficient X4 HIV-1 replication in primary CD4+T lymphocytes, a transcriptome analysis. Retrovirology, 2009, 6, 119.	0.9	2
58	New players in cytokine control of HIV infection. Current HIV/AIDS Reports, 2008, 5, 27-32.	1.1	43
59	Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells. BMC Biotechnology, 2008, 8, 85.	1.7	17
60	A dimerizable cationic lipid with potential for gene delivery. Journal of Gene Medicine, 2008, 10, 637-645.	1.4	24
61	Inhibition of Herpes Simplex Virus Types 1 and 2 In Vitro Infection by Sulfated Derivatives of Escherichia coli K5 Polysaccharide. Antimicrobial Agents and Chemotherapy, 2008, 52, 3078-3084.	1.4	25
62	Persistent Replication of Severe Acute Respiratory Syndrome Coronavirus in Human Tubular Kidney Cells Selects for Adaptive Mutations in the Membrane Protein. Journal of Virology, 2008, 82, 5137-5144.	1.5	50
63	Postgenomic up-regulation of CCL3L1 expression in HTLV-2–infected persons curtails HIV-1 replication. Blood, 2007, 109, 1850-1856.	0.6	34
64	Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: Possible protective effect of infecting HCV genotype on HIV disease progression. Journal of Clinical Virology, 2007, 39, 82-86.	1.6	13
65	Heterogeneity of Signal Transducer and Activator of Transcription Binding Sites in the Long-Terminal Repeats of Distinct HIV-1 Subtypes. The Open Virology Journal, 2007, 1, 26-32.	1.8	13
66	Immunopathogenesis of HIV Infection. , 2007, , 245-295.		2
67	Nef Alleles from Human Immunodeficiency Virus Type 1-InfectedLong-Term-Nonprogressor Hemophiliacs with or without Late Disease Progression Are Defective in Enhancing Virus Replication and CD4 Down-Regulation. Journal of Virology, 2006, 80, 10663-10674.	1.5	39
68	Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfusion Medicine, 2005, 15, 269-276.	0.5	35
69	Infection of CD4 + Primary T Cells and Cell Lines, Generation of Chronically Infected Cell Lines, and Induction of HIV Expression. Current Protocols in Immunology, 2005, 69, Unit 12.3.	3.6	4
70	<i>Coronaviridae</i> and SARS-associated Coronavirus Strain HSR1. Emerging Infectious Diseases, 2004, 10, 413-418.	2.0	127
71	Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons. Antiviral Therapy, 2004, 9, 1003-1011.	0.6	77
72	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. International Journal of Cancer, 2003, 107, 958-961.	2.3	8

#	Article	IF	CITATIONS
73	Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV*1. Vaccine, 2003, 21, 2052-2064.	1.7	24
74	Treatment of SARS with human interferons. Lancet, The, 2003, 362, 1158.	6.3	9
75	Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. Aids, 2003, 17, 177-181.	1.0	31
76	Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte–derived macrophages. Blood, 2003, 102, 2334-2337.	0.6	55
77	Tumor Necrosis Factorα, Interleukin 2, and Soluble Interleukin 2 Receptor Levels in Human Immunodeficiency Virus Type 1-Infected Individuals Receiving Intermittent Cycles of Interleukin 2. AIDS Research and Human Retroviruses, 2002, 18, 491-499.	0.5	8
78	Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4(+) T cells. Journal of Leukocyte Biology, 2002, 72, 913-20.	1.5	12
79	TUMOR NECROSIS FACTOR- $\hat{1}$ ± DRIVES HIV-1 REPLICATION IN U937 CELL CLONES AND UPREGULATES CXCR4. Cytokine, 2001, 13, 55-59.	1.4	18
80	Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Human Immunology, 2001, 62, 561-576.	1.2	55
81	Interleukin-6 and Glucocorticoids Synergistically Induce Human Immunodeficiency Virus Type-1 Expression in Chronically Infected U1 Cells by a Long Terminal Repeat Independent Post-Transcriptional Mechanism. Molecular Medicine, 2001, 7, 668-678.	1.9	21
82	Inhibition of R5X4 Dualtropic HIV-1 Primary Isolates by Single Chemokine Co-receptor Ligands. Virology, 2001, 280, 253-261.	1.1	19
83	The Binding Subunit of Pertussis Toxin Inhibits HIV Replication in Human Macrophages and Virus Expression in Chronically Infected Promonocytic U1 Cells. Journal of Immunology, 2001, 166, 1863-1870.	0.4	33
84	Efficacy of Lowâ€Dose Intermittent Subcutaneous Interleukin (IL)–2 in Antiviral Drug–Experienced Human Immunodeficiency Virus–Infected Persons with Detectable Virus Load: A Controlled Study of 3 ILâ€2 Regimens with Antiviral Drug Therapy. Journal of Infectious Diseases, 2001, 183, 1476-1484.	1.9	48
85	HTLV-II down-regulates HIV-1 replication in IL-2–stimulated primary PBMC of coinfected individuals through expression of MIP-1α. Blood, 2000, 95, 2760-2769.	0.6	43
86	CCR2â€64IPolymorphism, Syncytiumâ€Inducing Human Immunodeficiency Virus Strains, and Disease Progression. Journal of Infectious Diseases, 2000, 182, 1579-1580.	1.9	10
87	Shorter Survival ofSDF1â€3â€2A/3â€2AHomozygotes Linked to CD4+T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2000, 182, 311-315.	1.9	70
88	Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9162-9167.	3.3	41
89	Inhibition of CXCR4-Dependent HIV-1 Infection by Extracellular HIV-1 Tat. Biochemical and Biophysical Research Communications, 2000, 270, 992-996.	1.0	83
90	Human Immunodeficiency Virus Replication Induces Monocyte Chemotactic Protein-1 in Human Macrophages and U937 Promonocytic Cells. Blood, 1999, 93, 1851-1857.	0.6	92

#	Article	IF	CITATIONS
91	Human CD34+ Cells Express CXCR4 and Its Ligand Stromal Cell–Derived Factor-1. Implications for Infection by T-Cell Tropic Human Immunodeficiency Virus. Blood, 1999, 94, 62-73.	0.6	117
92	Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection. Blood, 1999, 94, 4202-4209.	0.6	77
93	Frequency of a Mutated CCR-5 Allele (Delta32) among Italian Healthy Donors and Individuals at Risk of Parenteral HIV Infection. AIDS Research and Human Retroviruses, 1999, 15, 337-344.	0.5	20
94	Defective nef Alleles in a Cohort of Hemophiliacs with Progressing and Nonprogressing HIV-1 Infection. Virology, 1999, 259, 349-368.	1.1	53
95	Envelope-Dependent Restriction of Human Immunodeficiency Virus Type 1 Spreading in CD4 ⁺ T Lymphocytes: R5 but Not X4 Viruses Replicate in the Absence of T-Cell Receptor Restimulation. Journal of Virology, 1999, 73, 7515-7523.	1.5	52
96	CCR2 Polymorphism and HIV Disease. Nature Medicine, 1998, 4, 252-253.	15.2	63
97	Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes. Journal of Experimental Medicine, 1998, 187, 439-444.	4.2	230
98	Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. Aids, 1998, 12, 1327-1332.	1.0	226
99	Rare mutations in a domain crucial for V3-loopstructure prevail in replicating HIV from long-term non-progressors. Aids, 1998, 12, 985-997.	1.0	27
100	1,25-Dihydroxyvitamin D3 Upregulates Functional CXCR4 Human Immunodeficiency Virus Type 1 Coreceptors in U937 Minus Clones: NF-κB-Independent Enhancement of Viral Replication. Journal of Virology, 1998, 72, 8380-8383.	1.5	27
101	Role of proinflammatory cytokines and β-chemokines in controlling HIV replication. Journal of Leukocyte Biology, 1997, 62, 34-40.	1.5	67
102	Transmission of HIV-1 and HCV by head-butting. Lancet, The, 1997, 350, 1370.	6.3	12
103	Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/Δccr5) genotype is neither essential nor sufficient for protection against disease progression. European Journal of Immunology, 1997, 27, 3223-3227.	1.6	39
104	Cytokines in the acquired immunodeficiency syndrome and other infectious diseases. International Journal of Clinical and Laboratory Research, 1995, 25, 128-134.	1.0	17
105	Ultraviolet irradiation and cytokines as regulators of HIV latency and expression. Chemico-Biological Interactions, 1994, 91, 101-109.	1.7	17
106	Regulation of HIV expression by viral genes and cytokines. Journal of Leukocyte Biology, 1994, 56, 328-334.	1.5	40
107	Ultraviolet Radiation Increases HIV-Long Terminal Repeat-Directed Expression in Transgenic Mice. AIDS Research and Human Retroviruses, 1991, 7, 729-733.	0.5	23
108	Platelet Contribution to Cancer Cell Growth and Migration: The Role of Platelet Growth Factors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1988, 18, 18-28.	0.5	6

#	Article	IF	CITATIONS
109	Dissociation between thromboxane generation and metastatic potential in cells from a murine fibrosarcoma. Studies with a selective thromboxane synthase inhibitor. International Journal of Cancer, 1987, 39, 488-491.	2.3	8
110	Platelet derived growth factor induces ornithine decarboxylase activity in nih 3T3 cells. Biochemical and Biophysical Research Communications, 1985, 127, 843-848.	1.0	11
111	Synthetic prostaglandin1 analogue: In vitro studies on human neutrophils. Immunopharmacology, 1982, 4, 323-330.	2.0	7